ARDS — Aridis Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
- $0.00m
- -$0.03m
- $3.09m
Annual income statement for Aridis Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 2.76 | 1.02 | 1 | 1.53 | 3.09 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 26.9 | 30.1 | 23.4 | 43.5 | 33.1 |
| Operating Profit | -24.1 | -29.1 | -22.4 | -42 | -30 |
| Total Net Non Operating Interest Income / Expense | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -22.1 | -29.7 | -22.3 | -42.2 | -30.4 |
| Net Income After Taxes | -22.1 | -29.7 | -22.3 | -42.2 | -30.4 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -22.1 | -29.7 | -22.3 | -42.2 | -30.4 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -23.5 | -29.7 | -22.3 | -46.3 | -30.4 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -2.89 | -3.51 | -2.44 | -3.83 | 10.5 |